This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site



Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Example content



AboutAboutTA OverviewMechanism of DiseaseDiagnosingDiagnosingSigns and SymptomsClinical CluesTreatmentTreatmentTreatment guidelinesPfizer Treatment OptionsStudies & InsightsSupporting ResourcesPatient Support & ResourcesPatient Support & ResourcesEventsMaterialsVideos
Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.Ulcerative Colitis

Crude incidence estimates between January 2000–31 December 2018. ‡Point prevalence estimates as on 31 December 20182 ​

UC=ulcerative colitis.​

1. Du L, Ha C. Gastroenterol Clin North Am. 2020;49(4):643−654. 2. Pasvol TJ, et al. BMJ Open. 2020;10(7):e036584. 
3. National Health Service (NHS). Patients Registered at a GP Practice September 2019. Accessed 26 July 2021. 
4. Høivik ML et al. Gut. 2013;62(3):368–375.
​​​​​​​5. Arnott I, et al. Inflamm Intest Dis. 2018; 2(4):189–199.

Disease activity and complications

CRC=colorectal cancer; EIM=extra-intestinal manifestation; UC=ulcerative colitis.​

Fumery M, et al. Clin Gastroenterol Hepatol. 2018;16(3):343−356.e3.

The interplay and determinants of incidence and prevalence of IBD and patient mortality rates

The true incidence of IBD is increasing due to factors associated with the Westernisation of society (dietary habits, antibiotic use, etc.)​

In parallel:​

  • Our ability to detect IBD has increased​
  • ​​​​​​​Our ability to better manage IBD, together with improvements in living standards generally, mean patients with IBD are living longer​

​​​​​​​In combination, these factors lead to an increase in the prevalence of IBD, and introduce the challenge of managing an increasingly ageing IBD population with potentially multiple comorbidities.

IBD=inflammatory bowel disease.​

Kaplan GG, Windsor JW. Nat Rev Gastroenterol Hepatol. 2021;18(1):56−66.

​​​​​​​Reproduced with permission from Kaplan GG, Windsor JW. 2021

UC prevalence and incidence: example data from NHS lothian, Scotland
Age at diagnosis for prevalent cases on 31/08/2018 overall. ‡Percentage prevalence is reported for age-appropriate population data derived from national records for Scotland; 2016-based projections for 2018.​

UC=ulcerative colitis.​

Jones JR, et al. Gut. 2019;68(11):1953−1960.

UC can lead to significant work disability 10 years after diagnosis† 
  • ​​​​​​​341 patients with UC followed up for 10 years (IBSEN population-based cohort)​
  • Relative risk for a disability allowance compared with the background population:​
  • All patients with UC = 1.80 (95% CI: 1.41–2.27)​
  • Patients with UC 30─39 years of age = 2.78 (95% CI: 1.44–5.38) 

Norwegian cohort study.​

CI=confidence interval; CRP=C-reactive protein; DA=disability allowance; ESR=erythrocyte sedimentation rate; IBSEN=Inflammatory Bowel in South Eastern Norway; UC=ulcerative colitis.​

Høivik ML et al. Gut. 2013;62(3):368–375.

Patients with UC are at significant risk of hospitalisation, colectomy and malignancy over time

ASCA=anti-Saccharomyces cerevisiæ antibody; CRC=colorectal cancer; CRP=C-reactive protein; ESR=erythrocyte sedimentation rate; pANCA=perinuclear anti-neutrophil cytoplasmic antibody; ​
UC=ulcerative colitis.​

Fumery M, et al. Clin Gastroenterol Hepatol. 2018;16(3):343−356.e3. 

Proportion of patients with UC undergoing colectomy has fallen since 2005

UC=ulcerative colitis.​

1. Jenkinson PW, et al. Colorectal Dis. 2020. doi: 10.1111/codi.15491. 2. Worley G, et al. Aliment Pharmacol Ther. 2020. doi: 10.1111/apt.16202.

Treatment challenges in UC

COVID-19=coronavirus disease of 2019; fCAL=faecal calprotectin; FMT=faecal microbial transplantation; RCT=randomised control trial; TDM=therapeutic drug monitoring; UC=ulcerative colitis.​

1. Danese S, et al. Dig Dis. 2019;37(4):266–283. 
2. Haberman Y, et al. Nat Commun. 2019;10(1):38. 
3. Peyrin-Biroulet L, et al. Am J Gastroenterol. 2015;110(9):1324−1338. ​
4. Lamb CA, et al. Gut. 2019;68(Suppl 3):s1−s106.  
5. Rahier JF, et al. J Crohns Colitis. 2014;8(6):443–468. 
6. Lees CW, et al. Gastroenterology. 2020;159(3):805−808. ​
7. Fumery M, et al. Clin Gastroenterol Hepatol. 2018;16(3):343−356.e3. 
​​​​​​​8. Crohn’s & Colitis Foundation. COVID-19 vaccines: What IBD patients & caregivers need to know. Accessed 26 July 2021.

Find out more about Xeljanz as a treatment option for moderate to severe UCXeljanz brand site  Loading
PP-XEL-GBR-3607. April 2022
Prescribing information: Xeljanz (tofacitinib) | Pfizer PI index - UK (Version 2.0)

Adverse events should be reported. Reporting forms and information can be found at or search 

for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

Copyright © 2021 Pfizer Limited. All rights reserved.

VAT registration number GB201048427

PP-UNP-GBR-0596. April 2022
For UK Healthcare Professionals *

hese pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

​​​​​​I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

​​​​​​​*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.​​​​​​​

​​​​​​​PP-PFE-GBR-3863. November 2021​​​​​​

Yes No
You are now leaving PfizerPro  
​​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​​​​​​​​
You are now leaving PfizerPro  
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021​​​​​​​

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?